Key result
CV pharmacotherapy trials prioritize hard clinical endpoints and total events over surrogate markers.
Answers are grounded in this paper and cite their sources.
Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.
No takes yet. Share an insight, caveat, or question.
Drexel et al. (2019) conducted a review in Cardiovascular disease, dyslipidemia, and diabetes. Cardiovascular pharmacotherapy was evaluated. Cardiovascular pharmacotherapy randomized clinical trials rely on recording clinically relevant hard endpoints and total events rather than surrogate markers.
Synapse has enriched 10 related papers. Consider them for comparative context: